President and CEOOfficers of the CorporationBoard of TrusteesFoundation BoardLeadership CouncilAbout Joslin ResearchAdvocacy & Gov't AffairsHistory
Managing DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsInfo for Healthcare ProfessionalsJoslin Clinical Guidelines50-Year Medalist Program
Patient PortalAdult ClinicPediatricsEye CareMake an AppointmentBillingInfo for Healthcare Professionals
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCommercialization and VenturesJoslin Institute for Technology Translation (JITT)
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

News Release

Tandem Diabetes Care, Inc. Joins The Joslin Institute for Technology Translation (JITT) As Founding Member

BOSTON (June 12, 2014) – Joslin Diabetes Center today announced that Tandem Diabetes Care®, Inc., a medical device company that designs and manufactures products for people with insulin-dependent diabetes, has joined the Joslin Institute for Technology Translation (the “Institute” or JITT) as a Founding Member and is a member of its Advisory Board. A new department of Joslin Diabetes Center, the Joslin Institute for Technology Translation is focused on leveraging the potential of technology with the introduction of clinical solutions and digital health to improve the lives of people with diabetes.

“Insulin pumps play a large role in diabetes technology innovation,” said Howard Wolpert, MD, Director of JITT.  “Our patients are interested in developing pump technologies. We are pleased to have Tandem Diabetes Care as a JITT Founding Member and we welcome the opportunities for advancing patient care that this collaboration will bring.”

"As a Founding Member of the JITT, Tandem is excited to collaborate with Joslin to provide new technologies for diabetes management," said Kim Blickenstaff, president and CEO, Tandem Diabetes Care, Inc. "This relationship will further our mission to develop innovative, user-centric diabetes devices that provide benefit to people with diabetes and health care providers alike."

Joslin Diabetes Center does not promote or endorse any product. Revenue and fees from the JITT will be invested in digital health to improve patient care.